New eye drops aim to calm Sjögren's dry eye by blocking inflammation
NCT ID NCT07671222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether eye drops containing infliximab, a drug that blocks a key inflammatory protein, can safely improve severe dry eye in people with Sjögren's syndrome. 38 adults will receive either the active drops or a steroid drop for 6 weeks. The study measures symptom changes and eye surface health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- infliximab eye drops
- What this could lead to
- If it works, this could offer a new, safer option for managing severe dry eye in Sjögren's syndrome by targeting inflammation directly.
- What could go wrong
- This is a small early-phase trial with only 38 people, so results may not apply widely. The treatment is topical but still carries risks like infection or irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto de Oftalmología Conde de Valenciana
Mexico City, Mexico City, 06800, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can acne drug harm the eyes? new study investigates
- Which eye drop wins the dry eye battle? a Head-to-Head test
- Can a new eye drop soothe dry eye? a trial puts TRYPTYR to the test
- New eye drop aims to soothe dryness after cataract surgery
- Can simple eye drops soothe dry eyes? new study puts OTC brands to the test
- New eye drop hopes to soothe dry eye sufferers